BR9714787A - Compostos de 4- fenilpiperidina e processo para sua preparação - Google Patents

Compostos de 4- fenilpiperidina e processo para sua preparação

Info

Publication number
BR9714787A
BR9714787A BR9714787-7A BR9714787A BR9714787A BR 9714787 A BR9714787 A BR 9714787A BR 9714787 A BR9714787 A BR 9714787A BR 9714787 A BR9714787 A BR 9714787A
Authority
BR
Brazil
Prior art keywords
group
alkyl
halogen
alkoxy
preparation
Prior art date
Application number
BR9714787-7A
Other languages
English (en)
Inventor
Francisco Bernardus G Benneker
Frans Van Dalen
Jacobus Maria Lemmens
Theodorus Hendricus Ant Peters
Frantisek Picha
Original Assignee
Synthon Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26647319&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9714787(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synthon Bv filed Critical Synthon Bv
Publication of BR9714787A publication Critical patent/BR9714787A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

COMPOSTOS DE 4-FENILPIPERIDINA E PROCESSO PARA SUA PREPARAçãO A invenção refere-se a um composto e sais farmaceuticamente aceitáveis, tendo a fórmula (I) na qual: R representa um grupo alquila ou alcinil tendo 1-4 átomos de carbono, ou um grupo fenil opcionalmente substituído por C~ 1-4~ alquila, alquiltio, alcoxi, halogênio, nitro, acilamino, metilsulfonil ou metilenodioxi, ou representa tetrahidronaftil; R^ 1^ representa hidrogênio, trifluor (C~ 1-4~) alquila, alquila ou alcinil; X representa hidrogênio, alquila tendo átomos de carbono 1-4, alcoxi, trifluoralquil, halogênio, metiltio ou aralcoxi; R^ 2^ representa um grupo alquila C~ 1~-C~ 10~; um grupo fenil opcionalmente substituído por um ou mais dos grupos seguintes: um grupo alquila C~ 1~-C~ 10~, um grupo halogênio, um grupo nitro, grupo hidroxi, e/ou um grupo alcoxi.
BR9714787-7A 1997-06-10 1997-06-10 Compostos de 4- fenilpiperidina e processo para sua preparação BR9714787A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/872,023 US5874447A (en) 1997-06-10 1997-06-10 4-Phenylpiperidine compounds for treating depression
PCT/NL1997/000328 WO1998056787A1 (en) 1997-06-10 1997-06-10 4-Phenylpiperidine compounds

Publications (1)

Publication Number Publication Date
BR9714787A true BR9714787A (pt) 2000-07-18

Family

ID=26647319

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9714787-7A BR9714787A (pt) 1997-06-10 1997-06-10 Compostos de 4- fenilpiperidina e processo para sua preparação

Country Status (25)

Country Link
US (4) US5874447A (pt)
EP (2) EP0994872B9 (pt)
JP (1) JP2002503248A (pt)
KR (1) KR100543614B1 (pt)
AT (1) ATE200781T1 (pt)
AU (1) AU3108097A (pt)
BG (1) BG64315B1 (pt)
BR (1) BR9714787A (pt)
CA (1) CA2293247C (pt)
CZ (1) CZ295301B6 (pt)
DE (2) DE69704679T2 (pt)
DK (1) DK0994872T3 (pt)
EE (2) EE03970B1 (pt)
ES (1) ES2155995T3 (pt)
GR (1) GR3035784T3 (pt)
HU (1) HUP0003141A3 (pt)
IL (1) IL133366A (pt)
IS (2) IS1927B (pt)
NO (3) NO317371B1 (pt)
PL (1) PL188450B1 (pt)
PT (1) PT994872E (pt)
SI (1) SI0994872T1 (pt)
SK (1) SK283394B6 (pt)
TR (2) TR199903025T2 (pt)
WO (1) WO1998056787A1 (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
EA200001050A1 (ru) * 1998-04-09 2001-04-23 Смитклайн Бичам Плс Малеат пароксетина
AU724845B3 (en) * 1998-07-02 2000-09-28 Smithkline Beecham Plc Novel compound
US20010023252A1 (en) * 1998-07-02 2001-09-20 Smithkline Beecham Plc Novel compound
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.
GB9814316D0 (en) * 1998-07-02 1998-09-02 Smithkline Beecham Plc Novel compounds
EP1102764A1 (en) * 1998-08-08 2001-05-30 Smithkline Beecham Plc Paroxetine salts
GB9827431D0 (en) * 1998-12-11 1999-02-03 Smithkline Beecham Plc Novel compound
GB9828779D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9828780D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9828781D0 (en) * 1998-12-29 1999-02-17 Smithkline Beecham Plc Novel process
GB9914585D0 (en) * 1999-06-22 1999-08-25 Smithkline Beecham Plc Novel process
ES2159260B1 (es) * 1999-06-22 2002-05-01 Smithkline Beechan Plc Nueva composicion de metanosulfonato de paroxetina
AU5078700A (en) * 1999-06-22 2001-01-09 Smithkline Beecham Plc Novel composition
KR100759159B1 (ko) * 1999-07-01 2007-09-14 이탈파마코 에스.피.에이. 파록세틴과 사이클로덱스트린 또는 사이클로덱스트린유도체의 컴플렉스
GB9919052D0 (en) * 1999-08-12 1999-10-13 Smithkline Beecham Plc Novel compound composition and process
US6503927B1 (en) * 1999-10-28 2003-01-07 Pentech Pharmaceuticals, Inc. Amorphous paroxetine composition
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
DK1286965T3 (da) * 2000-05-12 2004-05-03 Synthon Bv Piperidin-forbindelser og fremgangsmåder til fremstilling af sådanne
CZ20023694A3 (cs) * 2000-05-12 2003-05-14 Synthon B. V. Tosylátové soli 4-(p-fluorfenyl)-piperidin-3-methanolů
NZ523902A (en) * 2000-08-28 2004-05-28 Synthon Bv Paroxetine compositions and processes for making the same
WO2002022609A1 (en) * 2000-09-14 2002-03-21 Asahi Glass Company, Limited Process for producing paroxetine salt containing substantially no organic solvent
DE20100529U1 (de) * 2001-01-11 2001-05-10 Synthon Bv Pharmazeutische Tablette umfassend Paroxetinmesylat
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
NL1017421C2 (nl) * 2001-02-21 2002-01-15 Synthon Bv Werkwijze voor het vervaardigen van paroxetine.
US20030032809A1 (en) * 2001-04-25 2003-02-13 Subhash P. Upadhyaya Optimized procedures for the manufacture of paroxetine salts
AU2002318185A1 (en) * 2001-06-13 2002-12-23 Teva Pharmaceutical Industries Ltd. Process for the preparation of paroxetine substantially free of alkoxy impurities
IL159280A0 (en) * 2001-06-14 2004-06-01 Teva Pharma A process for preparing paroxetine hcl which limits formation of pink colored compounds
CA2456233A1 (en) * 2001-08-02 2003-03-13 Spurcourt Limited Paroxetine isethionate salt, process of preparation and use in the treatment of depression
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
WO2003082804A1 (en) * 2002-03-28 2003-10-09 Synthon B.V. Venlafaxine besylate
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
US7202259B2 (en) * 2002-11-18 2007-04-10 Euro-Celtique S.A. Therapeutic agents useful for treating pain
PL1691811T3 (pl) 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2006018318A1 (en) * 2004-08-18 2006-02-23 Synthon B.V. Liquid paroxetine compositions
WO2006023347A1 (en) * 2004-08-20 2006-03-02 Alpharma, Inc. Paroxetine formulations
KR101380190B1 (ko) * 2005-07-29 2014-04-11 콘서트 파마슈티컬즈, 인크. 벤조 〔ｄ〕〔１,３〕―디옥솔 유도체
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
US20070112031A1 (en) * 2005-11-14 2007-05-17 Gant Thomas G Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
SE529246C2 (sv) 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
US20080033050A1 (en) 2006-08-04 2008-02-07 Richards Patricia Allison Tewe Method of treating thermoregulatory disfunction with paroxetine
MX2010002692A (es) 2007-09-13 2010-06-01 Concert Pharmaceuticals Inc Sintesis de catecoles deuterados y derivados de benzo[d][1,3]dioxoles de los mismos.
US9138430B2 (en) * 2007-12-27 2015-09-22 Mylan Specialty L.P. Formulation and method for the release of paroxetine in the large intestine
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
WO2013115163A1 (ja) * 2012-01-31 2013-08-08 エーザイ・アール・アンド・ディー・マネジメント株式会社 パロキセチン誘導体
AU2013243461A1 (en) 2012-04-04 2014-11-06 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for combination therapy
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT99678B (de) * 1921-09-21 1925-04-10 Hoechst Ag Verfahren zur Darstellung arzneilich wirksamer Quecksilberverbindungen.
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
US4585777A (en) * 1984-02-07 1986-04-29 A/S Ferrosan (-)-Trans-4-(4-fluorophenyl)-3-(4-methoxyphenoxy)methylpiperidine for potentiating 5-HT
GB8430581D0 (en) * 1984-12-04 1985-01-09 Ferrosan As Treatment
EP0190496A3 (en) * 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
GB8520154D0 (en) * 1985-08-10 1985-09-18 Beecham Group Plc Chemical process
EP0223334B1 (en) * 1985-08-10 1991-07-10 Beecham Group Plc Process for the preparation of aryl-piperidine carbinols
EP0223403B1 (en) * 1985-10-25 1993-08-04 Beecham Group Plc Piperidine derivative, its preparation, and its use as medicament
US5258388A (en) * 1986-03-17 1993-11-02 University Of Florida Anticholinergic compounds, compositions and methods of treatment
IE66332B1 (en) * 1986-11-03 1995-12-27 Novo Nordisk As Piperidine compounds and their preparation and use
GB8626936D0 (en) * 1986-11-11 1986-12-10 Ferrosan As Treatment
GB8714707D0 (en) * 1987-06-23 1987-07-29 Beecham Group Plc Chemical process
DK716088D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Reduktion af piperidin-dion-derivater samt intermediat
DK715988D0 (da) * 1988-12-22 1988-12-22 Ferrosan As Etherifikation og dealkylering af piperidin-derivater samt intermediater
AU658155B2 (en) 1990-11-24 1995-04-06 Beecham Group Plc Use of paroxetine for the treatment of senile dementia, or anorexia
GB9209687D0 (en) * 1992-05-06 1992-06-17 Smithkline Beecham Plc Novel process
US5258517A (en) * 1992-08-06 1993-11-02 Sepracor, Inc. Method of preparing optically pure precursors of paroxetine
JP2773587B2 (ja) * 1992-11-30 1998-07-09 東レ株式会社 Ｏ，ｏ´−ジアシル酒石酸無水物の製造法
US5276042A (en) 1993-04-16 1994-01-04 Crenshaw Roger T Treatment of premature ejaculation
US5546683A (en) * 1993-09-29 1996-08-20 Clark; George J. Bucket attachment device with remote controlled retractable pins
IT1274241B (it) * 1993-12-03 1997-07-15 Smithkline Beecham Farma Complessi agente terapeutico/matrice polimerica dotati di migliorate caratteristiche di sapore e composizioni farmaceutiche che li contengono
GB9325644D0 (en) 1993-12-15 1994-02-16 Smithkline Beecham Plc Novel formulation
US5668134A (en) * 1994-01-28 1997-09-16 G. D. Searle & Co. Method for preventing or reducing photosensitivity and/or phototoxicity reactions to medications
GB9402029D0 (en) * 1994-02-03 1994-03-30 Smithkline Beecham Plc Novel formulation
CA2143070C (en) * 1994-02-22 2001-12-18 Pankaj Modi Oral controlled release liquid suspension pharmaceutical formulation
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
JPH08220486A (ja) * 1994-12-14 1996-08-30 Kato Kogei:Kk 眼鏡フレーム
AR001982A1 (es) * 1995-02-06 1998-01-07 Smithkline Beecham Plc Clorhidrato de paroxetina anhidratado, y procedimiento para su preparacion
GB2297550B (en) * 1995-02-06 1997-04-09 Smithkline Beecham Plc Paroxetine hydrochloride anhydrate substantially free of bound organic solvent
US5856493A (en) * 1995-02-06 1999-01-05 Smithkline Beecham Corporation Process for making novel form of paroxeting hydrochloride anhydrate
EP0818990A1 (en) * 1995-04-03 1998-01-21 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
CN1068597C (zh) * 1995-05-17 2001-07-18 诺沃挪第克公司 制备4－芳基－哌啶衍生物的方法
JP2813768B2 (ja) * 1995-05-24 1998-10-22 農林水産省家畜衛生試験場長 口蹄疫診断用ペプチドおよび当該ペプチドを含有する口蹄疫診断用抗原
GB9514842D0 (en) * 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
AU701386B2 (en) * 1995-10-31 1999-01-28 Merck & Co., Inc. Process for preparing substituted azetidinones
IT1276160B1 (it) * 1995-11-22 1997-10-27 Recordati Chem Pharm Composizioni farmaceutiche orali a pronto rilascio per sospensioni estemporanee
GB9526645D0 (en) * 1995-12-28 1996-02-28 Chiroscience Ltd Stereoselective synthesis
ES2117557B1 (es) * 1996-02-29 1999-07-01 Ferrer Int Nuevo procedimiento de obtencion de (-)-trans -n-p-fluorobenzoilmetil-4-(p-fluorofenil)-3- ((3,4-(metilendioxi)fenoxi ) metil)-piperidina.
JP3446468B2 (ja) * 1996-04-15 2003-09-16 旭硝子株式会社 ピペリジンカルビノール類の製造方法
CA2206592A1 (en) * 1996-05-30 1997-11-30 Shu-Zhong Wang Method of producing amorphous paroxetine hydrochloride
JP3882224B2 (ja) * 1996-05-31 2007-02-14 旭硝子株式会社 パロキセチンの製造方法
EP1394160A1 (en) * 1996-06-13 2004-03-03 SUMIKA FINE CHEMICALS Co., Ltd. Process for preparing crystalline paroxetin hydrochloride
HU221921B1 (hu) * 1996-07-08 2003-02-28 Richter Gedeon Vegyészeti Gyár Rt. N-benzil-piperidin- és tetrahidropiridinszármazékok és eljárás azok előállítására
US5672609A (en) * 1996-07-18 1997-09-30 Eli Lilly And Company Pyridine compounds, intermediates compositions and methods of use
CA2187128A1 (en) * 1996-10-04 1997-06-26 K. S. Keshava Murthy New and useful polymorph of anhydrous paroxetine hydrochloride
US5955475A (en) * 1997-06-30 1999-09-21 Endo Pharmaceuticals Inc. Process for manufacturing paroxetine solid dispersions
CH689805A8 (fr) * 1998-07-02 2000-02-29 Smithkline Beecham Plc Méthanesulfonate de paroxétine, procédé pour sa préparation et compositions pharmaceutiques le contenant.

Also Published As

Publication number Publication date
NO20033765D0 (no) 2003-08-25
WO1998056787A1 (en) 1998-12-17
TR199903025T2 (xx) 2000-07-21
TR200201156T2 (tr) 2002-07-22
PL188450B1 (pl) 2005-02-28
IS5249A (is) 1999-11-16
EE03970B1 (et) 2003-02-17
DK0994872T3 (da) 2001-05-28
US20010031767A1 (en) 2001-10-18
SK161999A3 (en) 2000-08-14
HUP0003141A3 (en) 2001-04-28
IS1927B (is) 2004-04-15
KR100543614B1 (ko) 2006-01-20
AU3108097A (en) 1998-12-30
CZ295301B6 (cs) 2005-07-13
KR20010013615A (ko) 2001-02-26
DE69704679T2 (de) 2001-09-13
US6900327B2 (en) 2005-05-31
HUP0003141A2 (en) 2001-03-28
ES2155995T3 (es) 2001-06-01
EE200200633A (et) 2003-02-17
PL336895A1 (en) 2000-07-17
US5874447A (en) 1999-02-23
SI0994872T1 (pt) 2001-08-31
NO20033765L (no) 2000-02-09
BG103980A (en) 2000-07-31
NO20033766D0 (no) 2003-08-25
EP0994872B9 (en) 2001-12-05
NO995455D0 (no) 1999-11-08
US20090326233A1 (en) 2009-12-31
EP1078925A1 (en) 2001-02-28
BG64315B1 (bg) 2004-09-30
IS7098A (is) 2004-01-08
IL133366A0 (en) 2001-04-30
CA2293247A1 (en) 1998-12-17
ATE200781T1 (de) 2001-05-15
HK1027352A1 (en) 2001-01-12
US7598271B1 (en) 2009-10-06
EP0994872A1 (en) 2000-04-26
JP2002503248A (ja) 2002-01-29
CA2293247C (en) 2005-04-12
NO995455L (no) 2000-02-09
GR3035784T3 (en) 2001-07-31
EP0994872B1 (en) 2001-04-25
SK283394B6 (sk) 2003-07-01
IL133366A (en) 2005-11-20
DE69704679D1 (de) 2001-05-31
NO20033766L (no) 2000-02-09
DE29724281U1 (de) 2000-08-10
CZ429599A3 (cs) 2000-04-12
NO317371B1 (no) 2004-10-18
PT994872E (pt) 2001-09-28
EE9900570A (et) 2000-08-15

Similar Documents

Publication Publication Date Title
BR9714787A (pt) Compostos de 4- fenilpiperidina e processo para sua preparação
BR9907300A (pt) Inibidores do fator xa oxoaza-heterociclila substituìdos
BR9814300A (pt) Método de preparação de óxidos de tetraidrobenzotiepina enanciomericamente enriquecidos
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
BRPI9917739B8 (pt) composto intermediário na preparação de inibidores de cox-2
BR9915727A (pt) ésteres derivados de compostos de fenil-ciclohexila substituìdos
BR0011597A (pt) Método para separar compostos orgânicos análogos e resina de troca iÈnica
BR9915735A (pt) Antagonistas receptores de ccr-3 de piperidina
BR0210285A (pt) Utilização de um composto, composto e composição farmacêutica
BR0008763A (pt) Derivados de piridopiranoazepinas, a preparação dos mesmos e a respectiva aplicação em terapêutica
BR9812892A (pt) 2 4-diamino-1,3,5-triazinas substituìdas e seu emprego como herbicidas
BR0100234A (pt) Compostos de piperidina-4-sulfonamida, processo para a sua preparação e composições farmacêuticas contendo os mesmos
BR9001734A (pt) Composto inseticida de diamino-etileno,processo para sua preparacao e composicao inseticida que o contem
BR9507381A (pt) Composto uso de um composto processo para o tratamento de um manifero composição famacèutica e processo para a preparação de compostos
BR0016921A (pt) Tetrahidropiridinas, processo para sua preparação e composições farmacêuticas que as contêm
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
BR9915692A (pt) Monohidrato de bromidrato de eletriptano
BR9705456A (pt) Compostos heterocìclicos, processo de aminometila para sua preparação e composições farmacêuticas que os contêm.
BR0106248A (pt) Inibidores de metaloprotease, processo para a sua preparação e composições farmacêuticas contendo os mesmos
PT937043E (pt) Novos derivados tetra-hidropiridinicos substituidos processo para a sua preparacao e as composicoes farmaceuticas que os contem
BR9903867A (pt) Compsto de indan-1-ol, processo para seu preparo e compostos farmacêuticos contento os mesmo
BR9909260A (pt) Processo para o preparo de (r)-alfa-(2,3-dimetóxifenil)-1-[2-(4-fluoro-fenil)etil]-4-pi peridinametanol
BR9806875A (pt) Processo para a preparação de um composto.
BR9908661A (pt) Compostos de 1,2-ditiolano, processo para sua preparação e composições farmacêuticas contendo-os
PT1347960E (pt) Processo para a preparacao de (+)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperidina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]